Erdem Türetken

Recent publications · Crossref

5 total works indexed

1. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

   · 2019 · cited 2,788x

2. Paraneoplastic anti– <i>N</i> ‐methyl‐ <scp>D</scp> ‐aspartate receptor encephalitis associated with ovarian teratoma

   · 2007 · cited 2,135x

3. Phy-X / PSD: Development of a user friendly online software for calculation of parameters relevant to radiation shielding and dosimetry

   · 2020 · cited 1,843x

4. Brand Equity as a Signaling Phenomenon

   · 1998 · cited 1,382x

5. Brands as Signals: A Cross-Country Validation Study

   · 2006 · cited 1,329x

via Crossref · CC0